Search Articles
MANHATTAN – Oriel Therapeutics sold itself too cheaply to Sandoz, shareholders says in a heavily redacted federal complaint, with a demand for $1 billion in punitive damages.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.